Tinnitus Talk submitted a new resource:
Phase 3 Clinical Trial: D-Methionine to Reduce Noise-Induced Hearing Loss (NIHL) (version 1.0) - To develop a safe, oral pharmacological agent to augment physical hearing protectors.
Read more about this resource...
Phase 3 Clinical Trial: D-Methionine to Reduce Noise-Induced Hearing Loss (NIHL) (version 1.0) - To develop a safe, oral pharmacological agent to augment physical hearing protectors.
This prospective study is a randomized, double-blind, placebo-controlled Phase 3 clinical trial of oral D-met to reduce noise-induced hearing loss (NIHL) and tinnitus. The goal of the study is to develop a safe, oral pharmacological agent to augment physical hearing protectors for noise exposures that exceed the protective capabilities of ear plugs and/or muffs. The study population is a cohort of Drill Sergeant (DS) instructor trainees during and 22 days after their 11 day weapons training....
Read more about this resource...